The global cell viability assays market is witnessing robust growth, valued at USD 1.89 billion in 2024, rising to USD 2.05 billion in 2025, and projected to reach USD 4.24 billion by 2034 at a CAGR of 8.54% from 2025 to 2034. This growth is driven by increased R&D investments, rising prevalence of chronic diseases, and the demand for high-throughput testing solutions.
This article explores market trends, key players, and dynamics shaping the future of this industry.
Market Overview and Dynamics
-
Market Size: USD 1.89 billion (2024) to USD 4.24 billion (2034)
-
CAGR: 8.54% (2025–2034)
-
Leading Region: North America (40% share in 2024)
-
Fastest Growing Region: Asia-Pacific
-
Top Product Segment: Reagents & Kits (65% share in 2024)
-
Emerging Segment: Instruments & Systems (expected rapid growth)
Key Drivers:
✅ Rising cancer and metabolic disorder cases
✅ Mandatory cytotoxicity testing by regulatory agencies
✅ Growth in personalized medicine and assay automation
Top Companies in the Cell Viability Assays Market
1. Thermo Fisher Scientific
About: A global leader in scientific services, Thermo Fisher focuses on life sciences solutions, analytical instruments, and specialty diagnostics.
Products: AlamarBlue, PrestoBlue Cell Viability Reagents, Countess II FL Automated Cell Counter.
Market Cap: Approx. USD 220 billion.
2. Merck KGaA (MilliporeSigma)
About: Operating as MilliporeSigma in the U.S. and Canada, Merck KGaA offers innovative solutions for life science research.
Products: CellTiter-Glo, CytoTox-One Assay Kits, SpectraMax Microplate Readers.
Market Cap: Approx. USD 90 billion.
3. Bio-Rad Laboratories
About: A pioneer in clinical diagnostics and life science research, Bio-Rad serves global laboratories with innovative products.
Products: TC20 Automated Cell Counter, Trypan Blue Dye Exclusion Kits.
Market Cap: Approx. USD 18 billion.
4. PerkinElmer Inc.
About: Known for precision instruments and assay platforms in diagnostics and life sciences.
Products: EnVision Multilabel Plate Readers, VICTOR Nivo Multimode Plate Reader.
Market Cap: Approx. USD 17 billion.
5. Promega Corporation
About: A privately held biotechnology company offering products for genomics, proteomics, and cellular analysis.
Products: CellTiter-Fluor, ApoTox-Glo Triplex Assays.
Market Cap: Privately held (~estimated USD 2.5 billion revenue).
6. Lonza Group AG
About: A Swiss multinational specializing in biotech and pharma contract development and manufacturing.
Products: ViaLight Plus Cell Proliferation Kit, Luminometer Systems.
Market Cap: Approx. USD 30 billion.
7. Abcam plc
About: Focuses on providing reagents, tools, and services for the global research community.
Products: MTT Cell Proliferation Assay Kits, Cell Viability Fluorometric Kits.
Market Cap: Approx. USD 4 billion.
8. BD Biosciences
About: A division of Becton, Dickinson and Company, offering tools for flow cytometry and cell analysis.
Products: BD FACSCanto Systems, Viability and Apoptosis Kits.
Market Cap: Parent company BD approx. USD 75 billion.
9. Agilent Technologies
About: Provides analytical instrumentation, software, and consumables for laboratories worldwide.
Products: Seahorse XF Analyzer, RealTime-Glo Cell Viability Assay Kits.
Market Cap: Approx. USD 40 billion.
10. Roche Diagnostics
About: A global leader in diagnostics and pharmaceuticals.
Products: xCELLigence RTCA Systems, Viability & Cytotoxicity Assays.
Market Cap: Parent Roche Holding AG approx. USD 220 billion.
11. Takara Bio Inc.
About: Specializes in biotechnology research products and gene therapy solutions.
Products: Cell Counting Kits (CCK-8), Apoptosis Assay Kits.
Market Cap: Approx. USD 2 billion.
12. GE Healthcare Life Sciences
About: A division of GE HealthCare offering cell biology and molecular biology products.
Products: Cytiva Viability Assays, Imaging Systems.
Market Cap: Parent GE HealthCare approx. USD 33 billion.
13. Enzo Life Sciences
About: Provides kits, reagents, and services for drug development and clinical research.
Products: ViaLight Plus ATP Monitoring System, Live/Dead Cell Assay Kits.
Market Cap: Approx. USD 120 million.
14. Qiagen N.V.
About: Specializes in sample and assay technologies for molecular diagnostics.
Products: QIAxpert Systems, MTT Cell Viability Assays.
Market Cap: Approx. USD 10 billion.
15. Corning Incorporated
About: Known for advanced materials and laboratory products, including cell culture technologies.
Products: Cell Counter, 96-Well Plate Assays for Cell Viability.
Market Cap: Approx. USD 25 billion.
16. Sigma-Aldrich (Part of Merck)
About: Offers chemicals, reagents, and kits for life science research and development.
Products: MTT and XTT Cell Viability Assay Kits, Microplate Readers.
Market Cap: Parent Merck KGaA included (~USD 90 billion).
17. Sartorius AG
About: A global leader in bioprocess solutions and lab products for life sciences.
Products: Incucyte Live-Cell Analysis Systems, Resazurin Cell Viability Assays.
Market Cap: Approx. USD 20 billion.
If you have any questions, please feel free to contact us at sales@towardshealthcare.com
Frequently Asked Questions (FAQs)
1. What is driving the growth of the cell viability assays market?
The market is driven by increasing R&D investments, demand for cytotoxicity testing, and advances in assay automation.
2. Which region dominates the cell viability assays market?
North America held a 40% revenue share in 2024, making it the leading region.
3. What is the expected CAGR of the market from 2025 to 2034?
The market is expected to grow at a CAGR of 8.54% during this period.
4. Which product segment holds the largest share?
Reagents and kits dominate with a 65% share in 2024.
5. Who are the top players in the market?
Top players include Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, and Roche Diagnostics.
Source : https://www.towardshealthcare.com/insights/cell-viability-assays-market-sizing
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5859
About the Author
